Floatz logo

il-12

Sarcoma

National Cancer Institute (NCI)Phase 1Dormant
C
38/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
26/ 100
Competitive Position
73/ 100

Competitive context

110 Active assets in the Sarcoma cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
Essen Biotech
Phase 2BB
Ifosfamide
City of Hope Medical Center
Phase 3BB
Inno-206
City of Hope Medical Center
Phase 3BB
Carboplatin
OHSU Knight Cancer Institute
Phase 2BB

View all 50 →

Same molecule, other indications

il-12 is also rated in:

metastatic melanomaDormant
CCC
Indicative ·
51 / 100
View asset →
renal cell carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
renal carcinomaDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →